Anticoagulant-related gastrointestinal bleeding—could this facilitate early detection of benign or malignant gastrointestinal lesions?

References

• Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006;333:726.
   PubMed Web of Science ®Google Scholar
• Ghate SR, Biskupiak J, Ye X, Kwong WJ, Brixner DI. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation. J Manag Care Pharm. 2011;17:672–84.
   PubMed Web of Science ®Google Scholar
• Guerrouij M, Uppal CS, Alklabi A, Douketis JD. The clinical impact of bleeding during oral anticoagulant therapy: assessment of morbidity, mortality and post-bleed anticoagulant management. J Thromb Thrombolysis. 2011;31:419–23.
   Google Scholar
• Barada K, Abdul-Baki H, El Hajj II, Hashash JG, Green PH. Gastrointestinal bleeding in the setting of anticoagulation and antiplatelet therapy. J Clin Gastroenterol. 2009;43:5–12.
   PubMed Web of Science ®Google Scholar
• Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95:315–28.
   PubMed Web of Science ®Google Scholar
• Asiimwe A, Li JJ, Weerakkody G, Vangerow H, Delisle F, Benoit K, et al. Diagnoses of gastrointestinal cancers after gastrointestinal bleeding in patients receiving clopidogrel or warfarin. Curr Drug Saf. 2013;8: 261–9.
   Google Scholar
• Jaffin BW, Bliss CM, LaMont JT. Significance of occult gastrointestinal bleeding during anticoagulation therapy. Am J Med. 1987;83:269–72.
   PubMed Web of Science ®Google Scholar
• Michaels MM. Bleeding from occult tumors during anticoagulant therapy. Circulation. 1962;25:804–6.
   Google Scholar
• Norton SA, Armstrong CP. Lower gastrointestinal bleeding during anticoagulant therapy: a life-saving complication? Ann R Coll Surg Engl. 1997;79:38–9.
   Google Scholar
• Bloom BJ, Filion KB, Atallah R, Eisenberg MJ. Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. 2014;113:1066–74.
   Google Scholar
• Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, et al. Factors associated with major bleeding events: insights from the ROCKET AF Trial (Rivaroxaban Once-daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol. 2014;63:891–900.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363–72.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.
   PubMed Web of Science ®Google Scholar
• Gallagher AM, van Staa TP, Murray-Thomas T, Schoof N, Clemens A, Ackermann D, et al. Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes. BMJ Open. 2014;4:e003839.
   Web of Science ®Google Scholar
• Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012;43:1511–17.
   PubMed Web of Science ®Google Scholar
• Wei H, Shang J, Keohane C, Wang M, Li Q, Ni W, et al. A novel approach to assess the spontaneous gastrointestinal bleeding risk of antithrombotic agents using Apc(min/+) mice. Thromb Haemost. 2014;111:1121–32.
   Google Scholar
• Merck Manual. Colorectal cancer. Available at: http://www.merckmanuals.com/home/digestive_disorders/tumors_of_the_digestive_system/colorectal_cancer.html (accessed 23 January 2014).
   Google Scholar
• RE-LY (ClinicalTrials.gov). Randomized evaluation of long term anticoagulant therapy (RE-LY) with dabigatran etexilate. Available at: http://clinicaltrials.gov/ct2/show/results/NCT00262600?term=dabigatran& recr=Completed&rslt=With&cond=atrial+fibrillation&phase=123&rank=3&sect=X43015 (accessed 21 January 2014).
   Google Scholar
• ROCKET AF (ClinicalTrials.gov). An efficacy and safety study of rivaroxaban with warfarin for the prevention of stroke and non-central nervous system systemic embolism in patients with non-valvular atrial fibrillation. Available at: http://clinicaltrials.gov/ct2/show/results/NCT00403767?term=rivaroxaban&recr=Completed&rslt=With&cond= atrial+fibrillation&phase=123&rank=1 (accessed 21 January 2014).
   Google Scholar
• ARISTOTLE (ClinicalTrials.gov). Apixaban for the prevention of stroke in subjects with atrial fibrillation (ARISTOTLE). Available at: http://clinicaltrials.gov/ct2/show/results/NCT00412984?term=apixaban& recr=Completed&rslt=With&cond=atrial+fibrillation&phase=123& rank=1&sect=X43015 (accessed 21 January 2014).
   Google Scholar
• EngageAFTIMI48 (ClinicalTrials.gov). Global study to assess the safety and effectiveness of edoxaban (DU-176b) vs standard practice of dosing with warfarin in patients with atrial fibrillation (EngageAFTIMI48). Available at: http://clinicaltrials.gov/ct2/show/NCT00781391?term= edoxaban&recr=Completed&cond=atrial+fibrillation&rank=1 (accessed 21 January 2014).
   Google Scholar
• Bytzer P, Connolly SJ, Yang S, Ezekowitz M, Formella S, Reilly PA, et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol. 2013;11:246–52.
   PubMed Web of Science ®Google Scholar
• Banke IJ, Arlt MJ, Mueller MM, Sperl S, Stemberger A, Sturzebecher J, et al. Effective inhibition of experimental metastasis and prolongation of survival in mice by a potent factor Xa-specific synthetic serine protease inhibitor with weak anticoagulant activity. Thromb Haemost. 2005;94:1084–93.
   Google Scholar
• Mousa SA, Linhardt R, Francis JL, Amirkhosravi A. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost. 2006;96:816–21.
   PubMed Web of Science ®Google Scholar
• Akl EA, Kamath G, Kim SY, Yosuico V, Barba M, Terrenato I, et al. Oral anticoagulation may prolong survival of a subgroup of patients with cancer: a Cochrane systematic review. J Exp Clin Cancer Res. 2007;26:175–84.
   PubMedGoogle Scholar
• Cunningham MS, Preston RJ, O’Donnell JS. Does antithrombotic therapy improve survival in cancer patients? Blood Rev. 2009;23:129–35.
   Google Scholar
• Letai A, Kuter DJ. Cancer, coagulation, and anticoagulation. Oncologist. 1999;4:443–9.
   PubMedGoogle Scholar
• Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer. 1984;53:2046–52.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol. 2009;27:4902–11.
   PubMed Web of Science ®Google Scholar
• Apixaban CDER review. Center for drug evaluation and research pharmacology reviews. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000PharmR.pdf (accessed 2 May 2014).
   Google Scholar
• Dabigatran SmPC. Pradaxa summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf (accessed 2 March 2014).
   Google Scholar
• Rivaroxaban EPAR. Committee for medicinal products for human use assessment report. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000944/WC500120736.pdf (accessed 2 May 2014).
   Google Scholar
• Tsopanoglou NE, Maragoudakis ME. Role of thrombin in angiogenesis and tumor progression. Semin Thromb Hemost. 2004;30:63–9.
   PubMed Web of Science ®Google Scholar
• Wu C-W, Sung JJ-Y. Colorectal cancer screening: are stool and blood based tests good enough? Chin Clin Oncol. 2013;2:8.
   Google Scholar
• Holme Ø, Bretthauer M, Fretheim A, Odgaard-Jensen J, Hoff G. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database of Systematic Reviews. Available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009259.pub2/references. (Accessed 6 March 2014).
   Google Scholar
• Kershenbaum A, Flugelman A, Lejbkowicz F, Arad H, Rennert G. Excellent performance of Hemoccult Sensa in organised colorectal cancer screening. Eur J Cancer. 2013;49:923–30.
   Google Scholar
• Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–7.
   PubMed Web of Science ®Google Scholar
• Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal- occult-blood test. Lancet. 1996;348:1467–71.
   PubMed Web of Science ®Google Scholar
• Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365–71.
   PubMed Web of Science ®Google Scholar
• Shaukat A, Mongin SJ, Geisser MS, Lederle FA, Bond JH, Mandel JS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013;369:1106–14.
   PubMed Web of Science ®Google Scholar
• Jorgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut. 2002;50:29–32.
   PubMed Web of Science ®Google Scholar
• Clarke P, Jack F, Carey FA, Steele RJ. Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening. Colorectal Dis. 2006;8:389–92.
   Google Scholar
• Sawhney MS, McDougall H, Nelson DB, Bond JH. Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non- steroidal anti-inflammatory drugs. Dig Dis Sci. 2010;55:1637–42.
   Google Scholar
• Konrad G, Katz A. Are medication restrictions before FOBT necessary? Practical advice based on a systematic review of the literature. Can Fam Physician. 2012;58:939–48.
   Google Scholar
• Mandelli G, Radaelli F, Paggi S, Terreni N, Gola G, Gramegna M, et al. Anticoagulant or aspirin treatment does not affect the positive predictive value of an immunological fecal occult blood test in patients undergoing colorectal cancer screening: results from a nested in a cohort case-control study. Eur J Gastroenterol Hepatol. 2011;23:323–6.
   Google Scholar
• Ashraf I, Paracha S, Paracha S, Arif M, Choudhary A, Godfrey JD, et al. Antithrombotics during fecal occult blood testing: a meta-analysis and systematic review. The Internet Journal of Gastroenterology. 2013;13.
   Google Scholar
• Bujanda L, Sarasqueta C, Lanas A, Quintero E, Cubiella J, Hernandez V, et al. Effect of oral anticoagulants on the outcome of faecal immunochemical test. Br J Cancer. 2014;110:1334–7.
   Google Scholar
• Goss AM, van Ryn J, Schurer J, Clemens A. Assessment of cross- reactivity in three different fecal occult blood test systems with dabigatran and dabigatran etexilate: identification of useful test methods. Blood. 2012;120: Abstr 4360.
   Google Scholar
• Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost. 2012;107:838–47.
   PubMed Web of Science ®Google Scholar
• Johannsdottir GA, Onundarson PT, Gudmundsdottir BR, Bjornsson ES. Screening for anemia in patients on warfarin facilitates diagnosis of gastrointestinal malignancies and pre-malignant lesions. Thromb Res. 2012;130:e20–e25.
   PubMed Web of Science ®Google Scholar
• Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer Systematic review and meta-analysis. Ann Intern Med. 2014;160:171–81.
   PubMed Web of Science ®Google Scholar